

### REMARKS

Reconsideration and allowance of this application is respectfully requested in view of the following remarks.

A restriction requirement has been imposed against the claims of the instant application. The Examiner contends that the claims describe several different inventions: Group I (claims 1-13), drawn to a method for preparing optionally substituted {N-[1-(S)-carbalkoxy-3-phenylpropyl]-S-alanyl-2S, 3aR, 7aS-octahydroindole-2-carboxylic acid}; Group II (claim 14), drawn to a crystalline polymorphic form A of trandolapril; Group III (claim 15), drawn to a crystalline polymorphic form B of trandolapril; Group IV (claims 16 & 17), drawn to a method of preparing polymorphic form A of trandolapril; Group V (claim 18), drawn to a method of preparing polymorphic form B of trandolapril; Group VI (claim 19), drawn to a method of preparing polymorphic form A of trandolapril; and Group VII (claim 20), drawn to a method of preparing polymorphic form B of trandolapril.

Applicant elects to prosecute Group I (claims 1-13).

Further, Applicant traverses the restriction of: A) Group IV and Group VI; and B) Group V and Group VII. With regard to

the former, A) Groups IV and VI, and based upon the Examiner's explanation, there is no difference, they are drawn to the same invention and the same class. Therefore, these Groups should be combined. Likewise, with the latter, there is no difference, and those Groups should be combined.

An early Notice of Allowance is respectfully requested.

Respectfully submitted,



---

Robert H. Hammer III  
Attorney for Applicant  
Registration No. 31,764

Customer No. 29494  
Hammer & Associates, P.C.  
3125 Springbank Lane  
Suite G  
Charlotte, NC 28226  
Telephone: 704-927-0400  
Facsimile: 704-927-0485  
H:\2084\007\Response092208.doc